Edwards Lifesciences Corp (NYSE:EW) saw unusually large options trading on Monday. Stock investors purchased 8,976 call options on the company. This represents an increase of approximately 1,311% compared to the average daily volume of 636 call options.

In related news, CEO Michael A. Mussallem sold 32,800 shares of the firm’s stock in a transaction on Thursday, January 3rd. The stock was sold at an average price of $143.90, for a total value of $4,719,920.00. Following the completion of the transaction, the chief executive officer now owns 75,926 shares in the company, valued at approximately $10,925,751.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Catherine M. Szyman sold 1,146 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $179.10, for a total value of $205,248.60. Following the completion of the transaction, the vice president now owns 22,229 shares of the company’s stock, valued at approximately $3,981,213.90. The disclosure for this sale can be found here. Insiders sold a total of 169,668 shares of company stock valued at $27,195,828 in the last 90 days. 1.84% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the company. Executive Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $25,000. Sontag Advisory LLC purchased a new position in Edwards Lifesciences in the 4th quarter valued at about $26,000. Lindbrook Capital LLC purchased a new position in Edwards Lifesciences in the 4th quarter valued at about $27,000. Capital Financial Planning LLC purchased a new position in Edwards Lifesciences in the 4th quarter valued at about $28,000. Finally, Nelson Roberts Investment Advisors LLC purchased a new position in Edwards Lifesciences in the 4th quarter valued at about $30,000. Hedge funds and other institutional investors own 83.09% of the company’s stock.

EW has been the subject of a number of research analyst reports. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their target price for the stock from $180.00 to $190.00 in a research note on Friday, January 18th. Citigroup raised their target price on Edwards Lifesciences from $118.00 to $119.00 and gave the stock a “sell” rating in a research note on Wednesday, January 2nd. Morgan Stanley raised their target price on Edwards Lifesciences from $180.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday. Deutsche Bank started coverage on Edwards Lifesciences in a research report on Wednesday, January 2nd. They set a “hold” rating and a $164.00 price target on the stock. Finally, UBS Group started coverage on Edwards Lifesciences in a research report on Tuesday, November 27th. They set a “neutral” rating and a $165.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. Edwards Lifesciences has a consensus rating of “Buy” and a consensus price target of $176.00.

Shares of EW opened at $189.36 on Wednesday. The stock has a market cap of $37.35 billion, a price-to-earnings ratio of 40.29, a P/E/G ratio of 2.32 and a beta of 0.90. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.92 and a current ratio of 2.61. Edwards Lifesciences has a fifty-two week low of $123.00 and a fifty-two week high of $197.86.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, January 31st. The medical research company reported $1.17 earnings per share for the quarter, hitting the consensus estimate of $1.17. The company had revenue of $977.70 million for the quarter, compared to the consensus estimate of $973.72 million. Edwards Lifesciences had a return on equity of 31.09% and a net margin of 19.40%. During the same period last year, the firm earned $0.94 EPS. On average, analysts expect that Edwards Lifesciences will post 5.21 EPS for the current year.

WARNING: “Edwards Lifesciences Target of Unusually Large Options Trading (EW)” was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/edwards-lifesciences-target-of-unusually-large-options-trading-ew/2902908.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Recommended Story: What is insider trading?

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.